List view / Grid view
A recent study from researchers at the University of California examines the BRCA2 gene, which plays a crucial role in repairing damaged DNA, and possible links with increased risk of breast and ovarian cancer.
Drug Target Review’s Ria Kakkad recently travelled to Barcelona to attend PEGS Europe’s Protein and Antibody Engineering Summit. In this article, she shares her highlights from the event.
Scientists have synthesised a new molecule that could kill a broad spectrum of hard-to-treat cancers, including triple-negative breast cancer, by exploiting a weakness in cells not previously targeted by other drugs.
9 June 2022 | By Eurofins DiscoverX
Watch this on-demand virtual roundtable to explore how the simple, thaw-and-use bioassay format improves assay workflow and helps attain high assay reproducibility.
Scientists identify a drug candidate to minimise erratic muscle movements, called dyskinesia, associated with Parkinson’s disease.
A new study prevented the growth of metastatic tumours in mice by forcing cancer cells into a dormant state, pointing to novel treatments.
Researchers discovered that cardiovascular damage was caused by reduced microRNA-210 levels in patient cells and mice with type 2 diabetes.
The small molecule successfully targeted the C9orf72 gene that causes amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
In a new study, a calorie-restricted diet significantly reduced tumour growth in mouse models, suggesting new possibilities for cancer therapies.
Medicenna's IL-2 super-agonist, MDNA11, successfully induced antitumour cells in animal models, a pre-clinical study has revealed.
Researchers identified three microRNAs whose levels were associated with mental performance in cells, mice and humans.
Boosting dendritic cells prevented immunotherapy resistance in mouse models, suggesting a new approach to colorectal cancer therapies.
Scientists have identified the OAS1 gene as a risk factor for both Alzheimer's disease and COVID-19, suggesting potential drug targets.
Scientists have identified a subpopulation of mesenchymal stem cells with enhanced bone fracture healing and differentiation abilities.
RGX-202 was found to foil a key pathway that cancer cells rely on for energy in mice, presenting a possible new colorectal cancer therapy.
